Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Dermatol Sci ; 110(3): 89-98, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37173222

RESUMEN

BACKGROUND: Biologics against IL-17A, IL-23 and TNF-α achieve a great success in treating psoriasis. However, the majority of patients still have some residual lesions left and require combination therapy to reach complete clearance. Topical medicine is an optional choice but only has limited categories. Besides, drug resistance is very often. Thus, topical medicine targeting new signaling pathway is still in an urgent need in the biologics era. OBJECTIVE: To investigate the role of topical Entinostat, a selective inhibitor of histone deacetylases 1 (HDAC1) that has been tested in clinic trials to treat solid tumors and hematological malignancies, in psoriasis therapy. METHODS: Efficacious Entinostat were tested in a mouse imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) model. An in vitro model consisting of human CD4 + T cell, murine T cells and NHEKs were used to screen Entinostat for inhibition of cutaneous inflammatory genes. RESULTS: Topical application of Entinostat significantly improved psoriasiform inflammation in imiquimod-induced mice model with great reduction of IL-17A+ Î³Î´T cell infiltration in skin. Entinostat is powerful agent in inhibition of Th17 cell generation and the expression of psoriasis-related inflammatory mediators by primary keratinocytes upon CD4+ T cells stimulation. CONCLUSION: Our findings suggest Entinostat is a promising topical medicine for psoriasis treatment.


Asunto(s)
Eccema , Psoriasis , Humanos , Animales , Ratones , Imiquimod/uso terapéutico , Interleucina-17/metabolismo , Histona Desacetilasa 1 , Piel/patología , Psoriasis/inducido químicamente , Psoriasis/tratamiento farmacológico , Psoriasis/patología , Modelos Animales de Enfermedad , Ratones Endogámicos BALB C
2.
Orthop Surg ; 14(10): 2470-2479, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-36029012

RESUMEN

OBJECTIVE: Musculoskeletal pain is having growing impacts worldwide with clinical challenge in pain management. The purpose of the present study is to investigate the preferences of orthopedic surgeons of China for using medicine in musculoskeletal pain. METHODS: A questionnaire was developed, including the following domains, personal information, medication preference for pain treatment, and perceptions of topical medicine. Ten participants were selected to confirm the consistency of questionnaire. A cross-sectional survey was conducted in orthopedic physicians with different specialties in different regions of China via the online survey platform. The participants' survey results were analyzed one-way and multi-way using chi-square test and logistic regression. RESULTS: The pre-survey analysis results of 10 randomly selected investigators were a mean weighted kappa coefficient of 0.76 (range 0.61-0.89), which indicated the substantial consistency of the present questionnaire. A total of 1099 orthopedic surgeons (mean age, 41.67 ± 8.31 years) responded to our survey, most of whom were male (90.72%), and most of whom worked in level III hospitals (63.24%) and trained in modern medicine (71.43%). Most surgeons who participated in the survey had used topical analgesics in their clinical work (95.81%), and most preferred to use topical analgesics (39.50%) or a combination of oral analgesics (28.87%). Primary reasons for preferring topical analgesics were as follows: less adverse reactions (68.01%); ease of use (60.90%); and not interfering with other oral medications (49.60%). The preference for prescribing topical analgesics increased with the education level of the respondent, where statistically significant differences were seen (P < 0.05). In addition, the level of the respondent's hospital, type of hospital, the respondent's profession, and their participation in surgical work influenced their preferences for topical analgesics (P < 0.05). CONCLUSION: Orthopedic surgeons across China have different medication preferences in the treatment of musculoskeletal pain. The educational background of the physician largely influences the preference when selecting medications. To better improve the treatment of musculoskeletal pain, there is a need to improve the overall medical education of practitioners and to disseminate clinical practice guidelines.


Asunto(s)
Dolor Musculoesquelético , Ortopedia , Adulto , Analgésicos/uso terapéutico , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dolor Musculoesquelético/tratamiento farmacológico , Manejo del Dolor
3.
Int Wound J ; 19(8): 2031-2038, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-35396823

RESUMEN

We performed a meta-analysis to evaluate the effect of Chinese herbal topical medicine, acupuncture, and moxibustion on pressure ulcer wound healing. A systematic literature search up to January 2022 was done and 13 studies included 1073 subjects with pressure ulcer wound at the start of the study; 593 of them were using traditional Chinese medicine treatments, and 480 were control for pressure ulcer wound. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) to evaluate the effect of Chinese herbal topical medicine, acupuncture, and moxibustion on pressure ulcer wound healing by the dichotomous methods with a random or fixed-influence model. Traditional Chinese medicine treatments had significantly higher complete healing (OR, 5.94; 95% CI, 3.94-8.95, P < .001), and curative ratio post-treatment (OR, 4.79; 95% CI, 2.62-8.76, P < .001) compared with control for subjects with pressure ulcer wound. Traditional Chinese medicine treatments had a significantly higher complete healing and curative ratio post-treatment compared with control for subjects with pressure ulcer wounds. Further studies are needed to validate these findings.


Asunto(s)
Terapia por Acupuntura , Moxibustión , Úlcera por Presión , Humanos , Úlcera por Presión/terapia , Cicatrización de Heridas , China
5.
Clin Pharmacol Drug Dev ; 7(5): 524-531, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29389078

RESUMEN

Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti-inflammatory molecules targeting the aryl hydrocarbon receptor. Study 201851 was an open-label, 2-cohort sequential study that assessed the systemic pharmacokinetics, safety, and efficacy of tapinarof in adults with moderate to severe atopic dermatitis. A total of 11 participants were enrolled: 5 received 2% cream, and 6 received 1% cream. Tapinarof was systemically absorbed, and measurable amounts were detected in both cohorts. Generally, plasma exposure was greater with the 2% cream and decreased from day 1 to day 21. Median Tmax ranged from 1 to 4 hours. Preliminary efficacy results were similar between the 1% and 2% concentrations, with the 1% cream showing better tolerability based on 3 subjects in the 2% cohort who discontinued treatment because of systemic AEs. The efficacy and safety of 1% tapinarof support results of previous positive studies that used a different formulation. However, conclusions in the present study are limited because of the open-label design and small number of participants. The 1% cream was selected as the concentration for use in future studies because of its lower AE incidence and efficacy comparable to the 2% cream.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Resorcinoles/administración & dosificación , Resorcinoles/farmacocinética , Estilbenos/administración & dosificación , Estilbenos/farmacocinética , Administración Tópica , Adulto , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resorcinoles/efectos adversos , Estilbenos/efectos adversos , Resultado del Tratamiento , Adulto Joven
6.
Ciênc. Saúde Colet. (Impr.) ; 20(11): 3599-3608, Nov. 2015. graf
Artículo en Portugués | LILACS | ID: lil-766404

RESUMEN

A avaliação comparativa exigida para registro das formulações tópicas genéricas no Brasil é feita por meio do estudo de equivalência farmacêutica que avalia apenas os parâmetros físico-químicos e microbiológicos dos medicamentos. Internacionalmente, estudos clínicos ou farmacodinâmicos vêm sendo exigidos para comprovar a eficácia e a segurança das formulações genéricas tópicas semissólidas. Este trabalho apresenta uma comparação entre os diferentes requerimentos para registro de uma formulação tópica, considerando diferentes autoridades regulatórias, e faz um levantamento dos produtos tópicos dermatológicos registrados no Brasil até 2013. Tal levantamento demonstrou haver uma grande quantidade de cópias desse tipo de formulação no Brasil em comparação com os EUA. Este fato, associado à grande quantidade de estudos encontrados na literatura demonstrando bioinequivalência de medicamentos tópicos, evidencia a grande importância de uma readequação da legislação brasileira no que se refere aos requisitos técnicos para o registro de medicamentos genéricos e similares de aplicação tópica dermatológica no Brasil.


The comparative evaluation required for the registration of generic topical medicines in Brazil is conducted by means of a pharmaceutical equivalence study, which merely assesses the physical/chemical and microbiological parameters of the formulations. At the international level, clinical or pharmacodynamic studies are now being required to prove the efficacy and safety of semisolid topical generic formulations. This work presents a comparison of the different requirements for the registration of topical formulations, taking into consideration the various regulatory authorities, and presents a survey of topical medicines registered in Brazil prior to 2013. The survey revealed that in comparison with the USA there were many more copies of these formulations registered in Brazil. This fact, together with the large number of studies in the literature showing the lack of bioequivalence of topical medication, is clear proof of the major importance of the need to realign Brazilian legislation with respect to the technical requirements for the registration of generic and similar medication for dermatological topical application in Brazil.


Asunto(s)
Humanos , Enfermedades de la Piel/tratamiento farmacológico , Equivalencia Terapéutica , Estados Unidos , Brasil , Administración Tópica , Medicamentos Genéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA